These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7111953)

  • 1. [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
    Honorato Pérez J; Azanza Perea JR
    Rev Med Univ Navarra; 1982 Mar; 26(1):51-4. PubMed ID: 7111953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 5. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W; Holm E
    Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A double blind study of the new hypolipidemic agent pirozadil (722-D) using patients with ischemic heart disease (author's transl)].
    Cadierno Carpintero M; Emeterio Reig E; Soler Masana JM
    Med Clin (Barc); 1982 May; 78(9):386-9. PubMed ID: 7047927
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
    Schwartzkopff W; Schilling A
    Med Welt; 1980 Dec; 31(50):1845-50. PubMed ID: 7464535
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H; Klein HJ
    Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lowering lipids rapidly and permanently with etofibrate].
    von Bock und Polach U
    Med Klin; 1982 Jan; 77(3):35-8. PubMed ID: 7057729
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lipanor treatment of atherogenic hyperlipoproteinemia].
    Susekov AV; Tvorogova MG; Arabidze GG; Kukharchuk VV
    Ter Arkh; 1998; 70(9):57-61. PubMed ID: 9821228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
    Steger W
    Fortschr Med; 1980 May; 98(18):(718-20). PubMed ID: 7390386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
    Fortschr Med; 1982 Sep; 100(35):1622-3. PubMed ID: 7173769
    [No Abstract]   [Full Text] [Related]  

  • 15. [Longterm therapy and etofibrate (author's transl)].
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P
    MMW Munch Med Wochenschr; 1980 Jan; 122(3):95-8. PubMed ID: 6767931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of bezafibrate on biliary lipids (author's transl)].
    Schlierf G; Fischer H; Roche A; Stiehl A; Oster P; Schellenberg B; Vollmar J
    MMW Munch Med Wochenschr; 1980 Feb; 122(5):165-8. PubMed ID: 6767944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R
    Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H
    Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R; Bochenek W; Unlot J
    Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
    [No Abstract]   [Full Text] [Related]  

  • 20. Plafibride treatment and serum lipids in hyperlipoproteinemias.
    Rodriguez F; López IM; Jover E
    J Med; 1987; 18(3-4):153-63. PubMed ID: 3323393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.